Omnichannel strategy Perspective
The Future of Pharma Omnichannel: When AI Becomes the Decision Layer
The next shift in pharma marketing may be the intelligence deciding what each channel should do—and the governance that determines what it may do.
The short version
AI could connect customer signals, approved content, evidence and permissions to recommend the next appropriate action across channels. Pharma leaders should prepare structured knowledge, explicit decision rights and measurable quality before expanding autonomy. The opportunity is better coordination with accountable human judgment.
For years, pharmaceutical omnichannel strategy has focused on coordinating channels. The website. Email. Paid search. Display. Social. CRM. Field engagement. Medical information. HCP portals. Patient support. The goal has been familiar:
Deliver the right information to the right person, through the right channel, at the right time.
AI may be about to change something more fundamental. The next phase of pharma digital transformation may not simply involve adding AI separately to websites, email, CRM, media and content production.
Instead, AI could increasingly become the decision layer sitting across those channels—continuously interpreting customer signals, available content, evidence, permissions, business objectives and performance to help determine what should happen next.
And evidence of that architecture is beginning to appear.
In October 2026, Real Chemistry launched MaestroHCP, an AI-powered platform designed specifically for pharmaceutical HCP omnichannel marketing. It combines audience intelligence, approved content, channel requirements and performance data with next-best-action deployment, investment decisioning and closed-loop measurement. The significance is not whether one vendor becomes the industry standard. It is that a pharma-specific platform is now explicitly organizing omnichannel around an intelligence layer rather than treating each channel as an independent execution environment. Real Chemistry
At the same time, Salesforce is moving AI upstream into customer research and simulation. Yext is connecting AI search visibility with paid and organic marketing execution. Adobe is redesigning digital experience architecture for an “agentic web.” Veeva is embedding industry-specific AI into CRM and PromoMats workflows. OpenAI is building agents capable of operating tools and computers while experimenting with advertising experiences that can become conversations rather than simple clicks.
These are primary sources for what vendors announced, not independent validation of performance or suitability for a particular pharma workflow. OpenAI’s Sponsored Agents are a test with selected U.S. advertisers, not an established pharma engagement channel. OpenAI
These should not be viewed as isolated product announcements. Together, they point toward a potentially much larger shift:
The future of pharma omnichannel may be less about coordinating channels and more about governing the intelligence that decides what each channel should do.
And if that shift continues, the next pharmaceutical customer journey may increasingly be co-authored by two AIs:
the AI representing the pharmaceutical organization and the AI representing the consumer or healthcare professional.
The short version: What is changing in pharma omnichannel?
Traditional omnichannel marketing is largely designed around predefined journeys and individual channels. An emerging agentic model looks different. Instead of asking only, “What should the website do?” or “Which email should we send?”, an intelligence layer could evaluate customer context, approved content, claims, evidence, safety requirements, consent, interaction history and channel rules before recommending the next appropriate action.
The channel then becomes an execution surface.
The intelligence layer increasingly supports the decision, within authority the organization has explicitly delegated. That could eventually reorganize how pharmaceutical organizations think about websites, search, CRM, paid media, field engagement, content operations, MLR and measurement. But there is an important distinction:
AI capability does not equal AI authority.
In regulated healthcare, the strategic advantage may come not from maximizing autonomy, but from knowing precisely what an AI system is permitted to know, recommend, assemble, execute and escalate.
Pharma omnichannel is starting to become an intelligence architecture
Consider how most omnichannel environments work today. Marketing teams define audiences. Teams develop communication plans. Agencies create content. MLR reviews it. Technology teams configure journeys. Media teams activate campaigns. Web teams manage destinations. CRM and field teams operate another set of interactions. Analytics teams measure everything afterward. Increasingly sophisticated technology connects these systems, but much of the intelligence still lives inside human meetings, PowerPoint decks, spreadsheets, agency briefs and manually configured decision trees.
Agentic AI creates the possibility of reorganizing that architecture. Imagine one governed environment continuously understanding: customer context, approved claims, supporting references, available content, channel permissions, consent, previous interactions, content expiration, performance signals, business objectives, and regulatory boundaries. Specialized AI systems could operate against that context. One agent might monitor search and AI visibility. Another might identify an HCP content gap. Another could detect an expiring asset.
Another could inspect whether a live webpage still matches its approved source. Another could evaluate campaign performance. Another might identify the supporting reference for a claim. Another could recommend whether an HCP should receive another digital interaction, a field follow-up, medical engagement—or nothing at all. Humans would still establish strategy, decision rights and regulatory boundaries. But AI could increasingly participate in the continuous interpretation and execution of that strategy.
Real Chemistry's MaestroHCP is one current signal of this direction. Veeva is describing its own evolution in similar terms through “Agentic Commercial,” with embedded AI connecting CRM, digital, field and commercial workflows. Veeva’s September 15 announcement describes Vault CRM as a foundation for agentic commercial engagement. This is a vendor description of its direction, not independent evidence of an integrated decision layer. Veeva
The emerging model increasingly resembles:
From coordination to decisions
Evaluate context → Recommend an action
That is fundamentally different from simply connecting more channels.
AI is moving upstream—before the campaign even exists
One of the most consequential developments may be happening before content production or activation.
Salesforce announced in September 2026 that it intends to acquire Listen Labs, an AI-powered customer-research and human-simulation company. Listen Labs' agents can design studies, conduct research and synthesize customer feedback. Salesforce says the technology can also help organizations simulate what customers may do and why. The announced acquisition remains subject to closing conditions; it is not a completed integration. Salesforce
That suggests another evolution. The first wave of marketing AI focused heavily on production:
write → generate → edit → publish.
Agentic marketing can move into execution:
analyze → recommend → activate → optimize.
But AI could move further upstream still:
listen → research → simulate → decide → plan → execute → measure → learn.
That matters. Imagine a pharmaceutical brand team considering several communication strategies. AI-generated simulations should not replace actual HCP research, patient research, scientific evidence or expert judgment. But simulation could become a hypothesis-generation environment. Teams could ask: How might different HCP segments interpret this concept? What questions might this message generate? Where could misunderstanding occur? What evidence would someone likely seek next? Which communications hypothesis deserves formal research?
Which information gaps are recurring across field, search, website and medical-information signals?
AI could help teams determine what deserves investigation before months of execution begin.
That moves AI from being primarily a production tool into the environment where strategy itself is developed.
How two AI assistants could influence the next HCP journey
Now consider the customer side. An oncologist needs information about a treatment option. Traditionally, that journey might begin with Google, a journal, a colleague, a representative or a pharmaceutical website. Increasingly, the starting point could be an AI assistant. The HCP asks:
“What manufacturer-supported information is available for this type of patient?”
Their AI identifies several authoritative sources. Perhaps the manufacturer's information enters the answer. Perhaps it does not. The HCP asks a follow-up question. The assistant retrieves more detail. Eventually the HCP may visit the manufacturer's website, review clinical evidence, request Medical Information or initiate another action. But something important has already occurred before that website visit:
AI helped define the consideration set.
That creates an entirely new strategic layer for pharmaceutical digital teams. For decades, marketers have optimized heavily around getting humans to destinations. The emerging question becomes:
Can an AI acting for that human correctly discover, interpret and trust the organization's authoritative information?
That extends the discovery problem beyond traditional click-through journeys.
Why pharma websites still matter in AI-mediated journeys
This is where predictions about the “death of websites” become too simplistic. Websites are likely to remain critically important. People will still need thoughtfully designed experiences for education, exploration, comparison, accessibility, evidence and trust.
But websites may increasingly serve two audiences simultaneously:
humans and machines acting for humans.
Adobe is already framing this as an architectural change. Its AEM materials describe AI systems reading and interpreting web content directly and argue that content increasingly needs to function as a dependable, structured system of record—not only as rendered webpages. Adobe
Recent consumer research also provides an interesting signal.
Attentive’s 2026 State of AI in Retail report surveyed U.S. consumers. Among respondents who had recently used general AI chatbots for shopping, 71% said AI meaningfully influenced which products or brands they seriously considered at least half the time they used it. Yet 93% still sought outside information or proof before purchasing. Sixty-four percent of those seeking outside proof used a seller's website, app or physical store, and 60% said they would prefer completing future purchases on the seller's website or app. Attentive
This is retail research, not healthcare research. The percentages should not be projected onto HCPs or patients. But the behavioral pattern is worth watching.
AI can influence what enters the consideration set without eliminating the need for authoritative destinations.
For healthcare, this suggests a hypothesis worth testing: authoritative destinations may retain an important verification role. The retail survey does not establish healthcare behavior. The future journey therefore may not be:
AI replaces website.
It may be:
AI discovery → authoritative verification → appropriate action.
And that creates a new strategic risk:
A pharmaceutical organization could lose the customer before the website visit ever occurs.
Traditional web analytics may never record that lost opportunity.
For AEM teams, the webpage may no longer be the smallest unit that matters
This has significant implications for pharmaceutical organizations running Adobe Experience Manager or other enterprise CMS platforms. Historically, the webpage has often been treated as a fundamental unit of digital experience. The agentic web puts pressure on that assumption. An AI system may need to understand not simply a page but the individual pieces of knowledge inside it: a claim, the indication associated with it, the supporting evidence, the intended audience, the applicable market, safety information,
approval status, publication date, expiration date, and relationships to other content. The future CMS therefore becomes more than a page-management system.
It becomes part of an authoritative knowledge and capability layer.
Adobe itself says AEM needs to accommodate a world in which AI systems can consume content outside conventional browser experiences and argues that content must become structured, reusable and dependable across new delivery surfaces. Adobe
For pharma organizations already investing in structured content and modular content, this gives those programs a much larger strategic purpose. Modularity is no longer only about producing content faster.
It can become part of making approved pharmaceutical knowledge machine-understandable and safely reusable.
GEO, SEO and agent readiness are becoming different problems
SEO is not disappearing.
Google says the same SEO foundations apply to AI Overviews and AI Mode: there is no special AI schema or additional machine-readable file required. Helpful content, crawlability, clear attribution and accurate structured data remain the foundation. Google Search Central
Search engines still matter. Websites still matter. But pharmaceutical digital strategy may increasingly have to optimize for three related—but different—questions.
SEO asks: Can search engines find, understand and rank this information?
GEO or answer-engine optimization asks: Can AI systems correctly retrieve, understand, summarize and attribute this information?
Agent readiness asks: Can an authorized AI system safely interact with the knowledge, data or capabilities underneath the experience?
That third category is important. A future customer AI may not simply retrieve a paragraph. It might eventually attempt an action. Request Medical Information. Locate support. Ask for an HCP resource. Find an approved clinical document. Schedule an appropriate interaction. Initiate an authenticated workflow.
The optimization problem therefore moves beyond content visibility toward safe machine interaction.
That requires structured information, identity, permissions and clear interfaces between AI systems and enterprise capabilities.
Marketing itself is starting to behave like a continuous system
Yext provides a useful example outside pharma. Yext
Its September 30 announcement describes a shared workspace for marketing teams and agents, building on AI search and competitive intelligence. The announcement describes a product direction; availability and integrations must be assessed separately. Its new shared workspace is designed so corporate teams, field teams, partners and AI agents can operate with common context rather than as independent tools. The specific vendor matters less than the pattern. Marketing platforms are beginning to combine:
sensing → analysis → recommendation → execution → measurement.
That may eventually challenge the organizational model surrounding digital marketing. Today, SEO, web, paid media, CRM, social, content, analytics and field teams frequently have separate tools, workflows and reporting systems. AI increasingly sees one connected decision problem. That does not mean companies should eliminate specialist teams.
It means the intelligence crossing those teams becomes increasingly shared.
For pharmaceutical organizations, the architecture requires an additional gate:
governance.
An AI system should not modify a claim, change targeting or generate a new promotional experience merely because performance data suggests it would improve engagement. A more plausible architecture is:
continuous sensing → AI recommendation → approved knowledge and content → policy check → authorized execution → monitoring
That difference is critical.
Why pharma AI needs traceable and reproducible decisions
Norstella announced a life-sciences platform on September 29, 2026.
Its new real-world-data agentic platform includes Atlas Patient Analytics, which helps biopharma teams construct patient cohorts. Norstella
The most important language in the announcement is not “agentic.”
Norstella describes the goal as producing a defensible, reproducible cohort from curated real-world data.
That phrase captures where regulated enterprise AI needs to go. The first era of generative AI asked:
Can the AI answer the question?
Regulated organizations increasingly need another standard:
Can we understand, reproduce and defend how it produced that answer?
Apply that to MLR. A weak AI system might say:
“This claim may be problematic.”
A more useful system would provide: the claim, the indication, the approved source, the evidence, the applicable audience, the current approval state, the specific issue identified, the previous relevant decision, and why human review is required. That is not replacing MLR.
It is improving the information environment surrounding human judgment.
Veeva is already moving in this direction. Its PromoMats AI capabilities include agents designed to perform document-quality checks, support claims libraries, identify and substantiate claims, and maintain traceability across marketing materials. Veeva also continues to describe humans and AI operating together in MLR workflows rather than presenting AI simply as unconstrained promotional automation. Veeva
Pharma's regulatory obligations do not disappear when the interface changes
This is where AI enthusiasm needs discipline.
FDA's Office of Prescription Drug Promotion states that prescription-drug promotion must be truthful, balanced and accurately communicated, and OPDP monitors internet-based promotion, including social media. FDA
The FTC’s broader health-products advertising guidance emphasizes that advertising must be truthful and not misleading, that objective health claims require appropriate substantiation, and that regulators consider the overall net impression communicated to consumers—not merely individual isolated sentences. FTC
FDA and FTC responsibilities differ by product and communication; this comparison does not imply identical jurisdiction. Changing the interface does not erase applicable obligations. A conversational interface can still communicate claims. An AI agent can still create an impression. A dynamic experience can still omit important context. An automatically assembled response can still present benefit and risk information inappropriately. Nothing in the public FDA sources cited here establishes autonomous AI approval of pharmaceutical promotional communication.
That leads to a principle pharma should carry into every agentic experiment:
Capability is not authority.
An AI system may technically be capable of generating, recommending, publishing, sending or responding. The organization still needs to determine whether it is permitted to do so.
Governance could become more valuable as AI improves
There is a popular version of the AI future where better models eventually eliminate most infrastructure. One intelligent model understands everything. Creates everything. Runs everything. That is unlikely to be the optimal architecture for regulated enterprises. The better AI becomes at executing work, the more valuable trustworthy organizational context becomes. The AI needs to know: What is true? What is approved? For which audience? For which indication? In which market? Supported by which evidence?
Under what permissions? Through what date? Who owns the information? What requires human review? What can never be delegated? Most pharmaceutical companies already possess this information. The problem is that it is often fragmented. Some sits in Veeva. Some in the CMS. Some in DAMs. Some in CRM. Some inside analytics platforms. Some inside PDFs. Some in spreadsheets. Some in SOPs. And a significant amount still resides in human expertise.
Agentic AI may expose that fragmentation very quickly. The companies best positioned for the next stage of AI may therefore not be those with access to the most powerful model. They may be those that have made their institutional knowledge:
structured, machine-usable, permission-aware, traceable and trustworthy.
The biggest disruption may ultimately be measurement
Suppose an HCP asks an AI assistant a treatment-related question. The AI retrieves accurate information from a manufacturer's authoritative digital content. The HCP receives the information they need. But they never click through to the website. What does the analytics dashboard record? Possibly nothing. That creates a serious measurement problem. For years, digital organizations have optimized around impressions, clicks, sessions, pageviews, email engagement and conversion events. Those measures will remain useful.
But AI-mediated customer journeys may require additional ways of understanding digital value. Organizations may eventually need to measure whether authoritative information appears correctly in relevant AI answers, whether claims remain connected to evidence, whether content carries reliable freshness and approval metadata, whether permitted agent tasks are completed correctly, whether systems escalate appropriately, and whether an AI attempts actions beyond its authorized scope. In other words:
The future dashboard may measure the performance of the information and decision system—not merely the performance of individual channels.
What pharmaceutical leaders should do now
None of this requires betting the business on a speculative 2030 future. Most of the underlying investments create value today.
1. Treat structured content as AI infrastructure.
Move beyond page-centric content toward modular knowledge with explicit relationships between audience, indication, claim, evidence, safety, market and approval status.
2. Make claim-to-evidence relationships explicit.
An AI system should not have to infer which reference supports a promotional claim.
3. Make approval status machine-readable.
Systems need to know what is usable, where, for whom and for how long.
4. Separate capabilities from applications.
Map what the enterprise can actually do—retrieve approved evidence, request Medical Information, initiate CRM activity, validate an asset, deliver an approved communication—then define who or what is allowed to invoke each capability.
5. Build evaluation and observability early.
Test factual accuracy, indication boundaries, safety behavior, unsupported claims, attribution, escalation and refusal behavior. Record what the agent knew, what it decided, what it did and why.
6. Begin measuring AI-mediated discovery.
Traditional SEO dashboards will not fully reveal how AI systems interpret or reuse authoritative pharma information. Separate observed referrals and authenticated outcomes from sampled AI visibility. A crawler visit does not prove citation, human exposure or impact; report those gaps and avoid collecting unnecessary sensitive data.
7. Redesign governance around shared intelligence.
Marketing, medical, regulatory, legal, technology, analytics and data cannot each develop independent agent strategies if the intelligence increasingly crosses every one of them.
The goal is not maximum automation.
The goal is trusted automation inside explicitly governed boundaries.
A plausible pharmaceutical customer journey three years from now
This is an illustrative 2029 scenario, not a forecast or a description of one deployed platform. It assumes validated permissions, appropriate consent, evaluated workflows and accountable human oversight. Commercial and medical responsibilities remain distinct; shared context does not mean unrestricted data sharing. Imagine planning a new communication strategy.
Instead of beginning with a blank PowerPoint deck, an intelligence environment continuously monitors market research, AI search behavior, web activity, CRM interactions, field insights, content inventory, medical-information themes, campaign performance and competitive signals. Research agents identify emerging questions. Simulation systems help pressure-test possible hypotheses. Humans determine which questions deserve formal research and which strategic direction the organization should pursue. A planning agent identifies audiences, communication gaps, content requirements and experiments.
Creative teams develop modular content with AI assistance. MLR-support agents inspect claims, references, metadata, approved language and content consistency before expert review. Humans remain accountable for consequential promotional decisions. Approved components enter a governed content environment. During execution, an orchestration system evaluates customer context and performance continuously. For one HCP, it recommends an approved email. For another, field engagement. For another, Medical Information. For a consumer whose consent has changed, it suppresses further communication.
For another person, the website remains the most useful experience. And when an AI assistant asks for authoritative information on behalf of an HCP, structured content can be retrieved with the appropriate evidence, context and controls intact. Marketing no longer manually predicts every possible customer journey months in advance. Leadership instead establishes:
strategy + objectives + trusted knowledge + constraints + permissions + measures of success.
AI helps interpret how those rules should be executed. That is a much bigger transformation than automating campaign production. It is a different operating model.
The next omnichannel transformation
The biggest mistake pharmaceutical organizations could make is treating today's AI developments as another collection of marketing tools. The deeper shift is architectural. OpenAI is building agents that can maintain context, use tools, work with files, run code and increasingly interact with computer environments. Adobe is preparing AEM for digital environments involving both humans and AI systems. Salesforce is bringing AI-driven customer research and simulation closer to CRM and marketing execution.
Veeva is embedding industry-specific AI into life-sciences CRM, content and MLR workflows. Real Chemistry is applying AI decisioning directly to HCP omnichannel orchestration. Yext is connecting AI-era discovery with marketing observation and execution. None of these developments tells us exactly what pharmaceutical marketing will look like several years from now. Together, however, they point in a remarkably similar direction.
The next generation of pharma marketing may not be organized primarily around channels.
It may be organized around governed intelligence.
And that creates a different question for pharmaceutical leaders:
If the next customer journey is increasingly negotiated between your company's AI and your customer's AI, is the knowledge underneath your organization structured well enough to be found, understood, trusted—and safely acted upon?
That may ultimately matter more than which chatbot a company deploys. Because in an agentic world, competitive advantage may not belong to the organization with the most AI. It may belong to the organization whose AI knows:
what is true, what is approved, what is appropriate, what is permitted—and when a human still needs to decide.
Frequently Asked Questions
What is agentic AI in pharmaceutical marketing?
Agentic AI refers to AI systems that can pursue goals using information, tools and workflows rather than only generating text. In pharmaceutical marketing, potential applications include campaign analysis, approved-content retrieval, website quality assurance, claims and reference checking, communication planning, next-best-action recommendations, MLR support and governed workflow execution.
How could AI change pharma omnichannel marketing?
AI could gradually move pharmaceutical omnichannel from manually configured journeys toward continuously interpreting customer signals, approved content, evidence, consent, permissions and channel rules. Humans would continue setting strategy and governance while AI helps recommend or execute permitted actions across web, CRM, email, media, field and medical channels.
Will AI replace pharmaceutical websites?
Current evidence does not support that conclusion. Websites are likely to remain important destinations for people seeking authoritative information and deeper evidence. Their role may expand as AI systems increasingly discover, interpret and retrieve structured content before a human ever visits the site.
What does agentic AI mean for Adobe Experience Manager?
For AEM environments, the strategic shift is from thinking only about rendering webpages toward maintaining structured, reusable and authoritative content that can also be understood by AI systems. That increases the importance of content models, metadata, APIs, evidence relationships, freshness and governance.
Does GEO replace SEO for pharmaceutical websites?
No. Traditional search, AI-mediated discovery and agent interaction are likely to coexist. SEO focuses on discoverability and ranking in search engines. GEO or answer-engine optimization focuses on accurate retrieval, interpretation, citation and representation by AI systems. Agent readiness adds another consideration: whether authorized AI systems can safely interact with underlying information or services.
Could AI replace pharmaceutical MLR review?
Current evidence does not support eliminating accountable human promotional judgment. AI is better suited to automating many mechanics surrounding review, including claims detection, reference validation, metadata checks, comparison with approved language, consistency checks, asset preparation and continuous digital QA.
What should pharma companies do now to prepare for agentic AI?
The most valuable near-term work is foundational: structure content and claims, connect claims explicitly to evidence, make approval state machine-readable, improve identity and consent data, define AI permissions, establish evaluation and monitoring, improve provenance and begin measuring how authoritative information appears inside AI-driven discovery experiences.
Primary sources and further reading
Sources checked October 2, 2026. Vendor announcements establish what was announced; the future architecture and recommendations are the author’s analysis.
- OpenAI — Introducing the Agents API
- OpenAI — Reimagining advertising with AI
- Adobe — Building the Agentic Web with AEM
- Salesforce — Listen Labs acquisition
- Real Chemistry — MaestroHCP
- Attentive — 2026 State of AI in Retail
- Norstella — RWD Agentic Platform
- FDA — Office of Prescription Drug Promotion
- Veeva — Vault CRM
- Veeva — AI for PromoMats
- Yext — Shared agent workspace
- FTC — Health Products Compliance Guidance
- Google — AI features and your website